RecruitingNot ApplicableNCT05992870

Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction


Sponsor

Hubei Cancer Hospital

Enrollment

40 participants

Start Date

Jul 8, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Neoadjuvant radiotherapy(NART) followed by mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. However, reports of NACT followed immediate implant-based breast reconstruction are rare. Some studies have shown that NART followed immediate implant-based breast reconstruction seems feasible and can be safely attempted. It's well known that radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results. So, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Inclusion Criteria4

  • Women \>18 years with histopathologically-confirmed breast cancer, who:
  • require mastectomy for any reason
  • a known indication for (adjuvant) radiotherapy
  • require implant-based breast reconstruction

Exclusion Criteria5

  • Inability to give informed consent
  • MDT unable to make recommendation for radiotherapy based on pre-operative histopathological and imaging findings
  • Previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla
  • Pregnant or lactating
  • inflammatory breast cancer

Interventions

RADIATIONNeoadjuvant radiotherapy

In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week. A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment.


Locations(1)

Xinhong Wu

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05992870


Related Trials